Abstract. This paper introduces a two-stage approach for evaluation of bioequivalence, where, in contrast to the designs of Diane Potvin and co-workers, two stages are mandatory regardless of the data obtained at stage 1. The approach is derived from Potvin's method C. It is shown that under circumstances with relatively high variability and relatively low initial sample size, this method has an advantage over Potvin's approaches in terms of sample sizes while controlling type I error rates at or below 5% with a minute occasional trade-off in power. Ethically and economically, the method may thus be an attractive alternative to the Potvin designs. It is also shown that when using the method introduced here, average total sample sizes are rather independent of initial sample size. Finally, it is shown that when a futility rule in terms of sample size for stage 2 is incorporated into this method, i.e., when a second stage can be abolished due to sample size considerations, there is often an advantage in terms of power or sample size as compared to the previously published methods.
INTRODUCTION
Diane Potvin and co-workers (1,2) introduced in 2008 some two-stage approaches for evaluation of bioequivalence and used trial simulations to investigate how the methods performed in terms of type I errors, power, and sample sizes. The methods involve initial trialing of N 1 subjects and evaluation of power or bioequivalence. It allows to stop after stage 1 when the products are bioequivalent or if the power at stage 1 is exceeding 80% and uses the variability observed at stage 1 to determine the sample size at stage 2. During my work with an agency in the ASEAN region, it came to my attention that while there is no specific guideline in that region that discusses two-stage approaches for evaluation of bioequivalence, the regulators expect two actual stages, meaning they do not expect the applicant to stop after stage 1 regardless of how the data look after stage 1. This in effect means that the Potvin designs are not desirable; in fact, there is to my knowledge not a single publication which shows the performance of any two-stage method where both stages are mandatory. The purpose of this work is therefore to introduce a variant of the Potvin designs which involves two mandatory stages and which controls type I errors at or below 5% and to use trial simulation to characterize it in terms of power and sample sizes, and to compare the performance with the method introduced by Potvin et al. for a population geometric mean ratio (GMR) of 0.95. Finally, the method is also evaluated when it is combined with a futility rule in terms of stage II sample size, at a GMR of 0.95.
MATERIALS AND METHODS
"Method E" Figure 1 shows an approach derived from Potvin's method C/D where two stages are mandatory. The principle is to use the variability at stage 1 to evaluate power at stage 1 after the initial N 1 subjects have been exposed to the investigational products. If the power is equal to or higher than 80%, then we include N 2 new subjects for stage 2 of the trial. If the power after stage 1 is lower than 80%, then we calculate a sample size N 2 for a target power of 80%, execute stage 2 with N 2 new subjects, and evaluate the pool of data from stage 1 and stage 2. The same alpha is applied for power and sample size calculation after stage 1 and for bioequivalence evaluation after stage 2. In this paper, I investigate how the method performs when N 2 is not lower than ½N 1 (N 2,min =½N 1 ); I will refer to this as "method E" to avoid confusion with Potvin's methods A, B, C, and D. Figure 2 illustrates how method E can be extended with a stopping rule in terms of sample size (N max ). In this paper, method E with futility rules is also being evaluated; this is done using the futility criteria applied previously (see next section).
Scenarios, Evaluation, and Software
As in the works by Potvin and Montague (1, 2) , scenarios with N 1 =12, 24, 36, 48, and 60 and coefficient of variations To identify an appropriate alpha for method E, the linear interpolation method described elsewhere (3) was used.
Futility rules are investigated under GMR=0.95 and are as follows:
RESULTS AND DISCUSSION Figure 3 shows how the appropriate alpha has been identified. The critical scenario (the scenario where the method displays the highest type I error) for GMR = 0.95 is N 1 = 12 and CV = 0.3; in this scenario, the type I error rate is controlled at 0.05 when the alpha is 0.0446, corresponding to derivation of a 91.08% confidence interval.
It is not possible to show all performance results in this paper; performance results not shown in this paper are available as Supplementary material online. In this paper, examples of performance are shown as figures. Figure 4 shows power for method E as function of N 1 for CV=20% and CV=40%. Figure 5 shows the type 1 error for method E as function of N 1 for CV=20% and CV=40%. Figures 6 and 7 show the corresponding plots for method E with the stopping rule N max =3×N 1 .
On comparison of the results obtained here with the results published by Potvin et al., sample sizes, e.g., the average sample sizes, are actually somewhat lower with method E as compared to method C at GMR=0.95 when the variation is relatively high and the initial sample size is relatively low. In these scenarios, this translates into a clear ethical advantage since the total exposure to investigational medicinal products is lower. There may be a minute trade-off in terms of power. As a rule of thumb, in terms of sample sizes, method E outperforms method C in scenarios that have a high tendency to go into a second stage, and conversely, Fig. 1 . Graphical description of method E. In contrast to the designs invented by Potvin et al., this approach always has two stages and a single alpha value is used at both stages. In this paper, the performance is investigated for N 2,min =½N 1 method E is inferior in terms of sample sizes for scenarios where method C has a low chance of going into a second stage. Interestingly, method E may be associated with another advantage: From all the tested combinations of N 1 and CV, it is clear that average sample sizes are relatively independent of initial sample sizes, and from this perspective, there is thus no good reason to start with high initial sample sizes, albeit low initial samples are associated with lowest power for a given CV and GMR. This contrasts strongly with the methods of Potvin where the lowest total sample size is often observed for the highest initial sample sizes (N 1 = 60). When futility rules are applied, we see similar patterns when the results are compared to Fugsang (4) .
In this work, N 2,min = ½N 1 has been investigated, but other ways to define N 2,min exist and deserve attention. Finally, it should be emphasized that even though the two-stage approaches are useful for situation when variabilities are unknown, applicants may in cases of high intra-subject variabilities (CV > 30%) have a good a l t e r n a t i v e b y u s i n g r e f e r e n c e -s c a l e d a v e r a g e bioequivalence
CONCLUSION
& Method E controls type I errors at or below 5% when alpha=0.0446 for GMR=0.95.
& Method E generally has a sample size advantage over method C/D in scenarios where method C/D have a high chance of going into stage 2. Method E is therefore an ethical and economical alternative to these methods. Similar conclusion applies when futility rules are applied.
& In terms of average total sample size, with method E, there is generally no apparent reason to start with a high sample size. 
